Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
69 hedge funds and large institutions have $438M invested in Ra Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 6 closing their positions.
164% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 11
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more capital invested
Capital invested by funds: $233M → $438M (+$205M)
11% more funds holding
Funds holding: 62 → 69 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.08M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.13M |
| 3 |
First Manhattan
New York
|
+$3.51M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.38M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$14.7M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.19M |
| 3 |
Millennium Management
New York
|
-$1.99M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$515K |
| 5 |
Goldman Sachs
New York
|
-$495K |
RARX Hedge Fund Activity: Q3 2018 in Review
69 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q3 2018, worth a combined $438M — up 88% from $233M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RARX positions and 6 closed out — a net gain of 7 holders — while 29 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $6.08M. The largest seller was Novo Holdings A/S, cutting an estimated $14.7M.
- 69 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q3 2018, up from 62 in Q2 2018.
- Funds reported $438M of Ra Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 88% quarter-over-quarter.
- 13 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 6 closed out, a net change of +7 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was BlackRock, an estimated $6.08M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Novo Holdings A/S, an estimated $14.7M sold.
Based on aggregated 13F filings for Q3 2018.